Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accumulated Depreciation (2023 - 2025)

Cardiff Oncology (CRDF) has disclosed Accumulated Depreciation for 8 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 7.98% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 7.98% year-over-year, with the annual reading at $4.5 million for FY2025, 7.98% up from the prior year.
  • Accumulated Depreciation hit $4.5 million in Q4 2025 for Cardiff Oncology, up from $4.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $4.5 million in Q4 2025 to a low of $3.8 million in Q4 2023.
  • Historically, Accumulated Depreciation has averaged $4.2 million across 3 years, with a median of $4.2 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation: rose 10.26% in 2024 and later grew 7.98% in 2025.
  • Year by year, Accumulated Depreciation stood at $3.8 million in 2023, then increased by 10.26% to $4.1 million in 2024, then increased by 7.98% to $4.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation for CRDF at $4.5 million in Q4 2025, $4.4 million in Q2 2025, and $4.2 million in Q1 2025.